Literature DB >> 34930757

Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns.

Elisabeth Mahase1.   

Abstract

Entities:  

Year:  2021        PMID： 34930757     DOI： 10.1136/bmj.n3127

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review.

Authors:  Federico Emanuele Pozzi; Elisa Conti; Ildebrando Appollonio; Carlo Ferrarese; Lucio Tremolizzo
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

Review 2.  Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.

Authors:  Miguel Vaz; Vítor Silva; Cristina Monteiro; Samuel Silvestre
Journal:  Clin Interv Aging       Date:  2022-05-18       Impact factor: 3.829

3.  Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis.

Authors:  Anna Sampietro; F Javier Pérez-Areales; Paula Martínez; Elsa M Arce; Carles Galdeano; Diego Muñoz-Torrero
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-28

4.  A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer's Disease Mice Models.

Authors:  Júlia Jarne-Ferrer; Christian Griñán-Ferré; Aina Bellver-Sanchis; Santiago Vázquez; Diego Muñoz-Torrero; Mercè Pallàs
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-22

Review 5.  The Potential of Small Molecules to Modulate the Mitochondria-Endoplasmic Reticulum Interplay in Alzheimer's Disease.

Authors:  Giacomo Dentoni; Laura Castro-Aldrete; Luana Naia; Maria Ankarcrona
Journal:  Front Cell Dev Biol       Date:  2022-08-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.